Saphnelo

Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus (SLE).[1][2] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.[medical citation needed] Anifrolumab was approved for medical use in the United States in August 2021.[1][3][4][5... [wikipedia]